



SMAR014
80021-257

#5
fre
Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SALARI, Hassan *et al.*

Serial No.: 09/852,424

Filed: 9 May 2001

Title: CXCR4 ANTAGONIST TREATMENT
OF HEMATOPOIETIC CELLS

Examiner: N/A

Group Art Unit: N/A

17 September 2001

Preliminary Amendment

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to Examination of the above referenced application, please enter the following amendments.

AMENDMENT

In the Specification:

Please replace line 15 on page 5 with the following rewritten line:

DNA techniques, a selected nucleic acid, such as a gene, may be isolated, placed

ne

Please replace the paragraph beginning at page 17, line 8, with the following rewritten paragraph:

A variety of small SDF-1 peptide analogues may also be used as CXCR4 antagonists, as disclosed in International Patent Publications WO 00/09152 (published 24 February 2000) and WO 99/47158 (published 23 September 1999), each of which is incorporated herein by reference. One such peptide may be a monomer having the following sequences: GVSLSYRCPCRFFESH (SEQ ID No. 13); KGVLSYRC (SEQ ID No. 14), or dimer of amino acids 1-9 (within SEQ ID No. 13), in which the amino acid chains are joined by a disulphide bond between each of the

Q1